Glucagon Capsules

Glucagon Capsules, as an endogenous peptide regulator with a broad-spectrum and pleiotropic regulatory profile, is a key mediator within the gut-pancreas-heart-brain axis regulatory network. One of its core physiological regulatory effects is precisely focused on the field of anti-inflammatory protection for cardiac and neural tissues. It does not exert its effects through non-specific anti-inflammatory actions. Instead, by targeting and recognizing inflammatory initiation hubs and cascade amplification pathways, it precisely intervenes in the spatiotemporal regulatory process of the inflammatory response. This effectively inhibits the synthesis and release of inflammatory mediators and the infiltration and recruitment of inflammatory cells, thereby mitigating pathological tissue damage mediated by inflammation. Consequently, it stabilizes the physiological homeostasis and functional synergy of the heart-brain axis, providing indispensable core regulatory support for the histological integrity, cellular phenotypic stability, and physiological functional homeostasis of cardiac and neural tissues. Its anti-inflammatory and protective effects permeate the entire process of physiological defense and injury repair in both the heart and nervous system.

 

Our Product Forms

 

​

Glucagon COA

As the core power organ of the body's circulatory system, the stable operation of cardiac tissue's physiological functions is highly dependent on the integrity of its tissue microenvironment. Inflammatory responses are a primary initiating factor for pathological myocardial injury and cardiac dysfunction.Various stress stimuli (such as ischemia-reperfusion injury, oxidative stress overload, endotoxin stimulation, etc.) can activate inflammatory response pathways in myocardial tissue.

This induces the adhesion, infiltration, and recruitment of inflammatory cells in the myocardial interstitium, disrupting the dynamic balance between cardiomyocytes and the interstitium. This leads to an imbalance in the myocardial tissue microenvironment homeostasis, subsequently causing metabolic disturbances and functional abnormalities in cardiomyocytes. If prolonged, this can trigger severe pathological changes such as myocardial remodeling and heart failure. Glucagon, as a key peptide factor in the cardiac inflammatory regulatory network, does not exert its effects through non-specific anti-inflammatory actions. Instead, by precisely targeting the core nodes of cardiac inflammation regulation, glucagon capsules inhibit the initiation, amplification, and perpetuation of the inflammatory cascade, mitigating inflammation-mediated myocardial injury at its source. This confers specific and efficient cardioprotective effects, with specific benefits detailed below:

01.Inhibiting Myocardial Inflammatory Infiltration and Reducing Myocardial Parenchymal Injury:

This medicine can specifically recognize and bind to it receptor subtypes (GCGR) on the membrane surface of cardiomyocytes, initiating the cascade activation of the intracellular cAMP/PKA signaling pathway. It subsequently targets and regulates the activation and assembly process of the NLRP3 inflammasome, a key inflammatory hub in myocardial tissue. Specifically, it can inhibit the binding of NLRP3 with the ASC adapter protein, suppressing the oligomerization and assembly of the inflammasome. This reduces the synthesis and release of inflammasome-mediated pro-inflammatory mediators (such as leukotriene B4, prostaglandin E2, and thromboxane A2), effectively cutting off the initial triggering step of the inflammatory signal. Building on this, it further inhibits the expression of adhesion molecules (ICAM-1, VCAM-1) on the surface of myocardial microvascular endothelial cells.

This impedes the adhesion and trans-endothelial migration of inflammatory cells like neutrophils and macrophages, reducing their infiltration and recruitment into the myocardial interstitium. This precise regulation effectively mitigates the damage to cardiomyocytes caused by toxic substances released upon inflammatory cell activation, such as proteases and oxygen free radicals. It helps prevent pathological changes in cardiomyocytes like edema, necrosis, myofibril rupture, and myocardial fiber degeneration. Simultaneously, it reduces abnormal collagen fiber deposition in the myocardial interstitium, lowers the risk of myocardial interstitial fibrosis, and averts irreversible damage to the myocardial tissue structure. By maintaining the integrity of the myocardial parenchyma and the stability of the cellular phenotype, it lays a solid histological foundation for the stable performance of cardiac systolic and diastolic functions.

02.Stabilizing the Myocardial Microenvironment and Enhancing Cardiac Stress Resistance:

Glucagon regulates the expression levels of anti-inflammatory cytokines (such as IL-10, TGF-β) within the myocardial tissue. This is achieved specifically by activating the STAT3 signaling pathway, which mediates the transcriptional upregulation of IL-10, while simultaneously inhibiting the activation of the NF-κB signaling pathway. This action balances the dynamic disequilibrium between pro-inflammatory and anti-inflammatory signals, optimizing the homeostasis of the myocardial interstitial microenvironment. Concurrently, it specifically inhibits the abnormal activation of cardiac fibroblasts by suppressing the activation of the Smad pathway, reducing their transformation into myofibroblasts.

This, in turn, diminishes the excessive deposition of extracellular matrix components (such as fibronectin, vimentin, and laminin), thereby preserving the elasticity and compliance of myocardial tissue and preventing issues like tissue stiffness and reduced contractile function. Furthermore, glucagon capsules can enhance the energy metabolism efficiency of cardiomyocytes by activating the AMPK signaling pathway. This boosts their tolerance to adverse stress stimuli such as ischemia, hypoxia, and oxidative stress, lowering the risk of stress-induced cardiac inflammatory injury. It reduces cardiomyocyte apoptosis and functional abnormalities under stress conditions, ensuring the stable operation of the heart's pumping function and further strengthening the physiological defense capacity of the heart.

As the central hub for signal transduction and functional regulation in the body, neural tissue is composed of neurons, glial cells, and nerve fibers. The integrity of its physiological function is highly dependent on the homeostasis of its tissue microenvironment and exhibits extreme sensitivity and vulnerability to inflammatory damage. The persistent activation of inflammatory responses is a core trigger for pathological damage in neural tissue. When the body is affected by factors such as stress stimuli, infection, or metabolic abnormalities, the inflammatory response pathways within neural tissue can become aberrantly activated. This, in turn, induces abnormal activation and proliferation of glial cells, which release a large number of pro-inflammatory mediators and neurotoxic substances. This leads to axonal degeneration, demyelination, and even neuronal apoptosis.

Over time, this can trigger disorganization of the neuropil structure and the formation of glial scars, resulting in neurological dysfunctions affecting sensation, movement, cognition, and other areas, severely impacting normal physiological activities. Glucagon, as a specific peptide regulator within the neural inflammatory regulatory network, does not exert its neuroprotective effects through non-specific anti-inflammatory actions. Instead, by precisely targeting the core signaling nodes of inflammation regulation in neural tissue, it accurately intervenes in the initiation, cascade amplification, and perpetuation of the inflammatory response. It mitigates inflammation-mediated neural tissue damage at its source, maintaining the structural integrity and functional stability of neural tissue, and exerting efficient and specific neuroprotective effects. The specific benefits are manifested in this following spect: 

Inhibitig Excessive Activation of Glial Cells and Suppressing the Neural Inflammatory Cascade:

Glial cells, the primary supporting cells of neural tissue, include microglia, astrocytes, and oligodendrocytes. Among these, microglia and astrocytes are the core effector cells in the neural inflammatory response, and their abnormal activation is a key step in the initiation and amplification of neuroinflammation. It can specifically recognize and bind to glucagon capsules receptor subtypes (GCGR) and related co-receptors on the membrane surface of glial cells. This initiates the cascade activation of intracellular signaling pathways, such as the cAMP/PKA and JAK/STAT pathways, thereby precisely inhibiting the abnormal activation and proliferation of microglia and astrocytes.

It suppresses their transformation from a resting phenotype to a pro-inflammatory activated phenotype (e.g., microglial M1 type, astrocytic A1 type). This regulation significantly reduces the release of pro-inflammatory cytokines (e.g., IL-1β, TNF-α, IL-6) from activated glial cells. Simultaneously, it inhibits the synthesis and release of neurotoxic substances, including nitric oxide and excitatory amino acids like glutamate and aspartate.The excessive release of glutamate, in particular, leads to excitotoxicity, a major mechanism of neuronal damage. Glucagon can mitigate this excitotoxic damage by inhibiting the abnormal expression of glutamate transporters, thereby reducing the accumulation of glutamate in the synaptic cleft.

Furthermore, by upregulating the expression of anti-inflammatory cytokines (e.g., IL-4, IL-13), it helps balance the dynamic equilibrium between pro-inflammatory and anti-inflammatory signals within the neural tissue.This effectively curbs the amplification and perpetuation of the neural inflammatory cascade, preventing pathological damage to neuronal cell bodies, axons, and myelin sheaths caused by inflammatory mediators. It helps maintain the normal morphology and electrophysiological function of neurons, reduces the occurrence of neuronal apoptosis, and inhibits the excessive formation of glial scars, thereby providing a safeguard for the structural and functional homeostasis of neural tissue.

Glucagon exerts a dual protective effect by precisely targeting and regulating inflammatory responses in both cardiac and neural tissues. The benefits of its action are centrally manifested in mitigating myocardial inflammatory injury and stabilizing cardiac functional homeostasis, as well as in inhibiting neuroinflammation and safeguarding neurological function integrity. By precisely intervening at key inflammatory regulatory nodes and balancing pro-inflammatory and anti-inflammatory signals, this function provides an essential safeguard for the physiological homeostasis of the heart and neural tissues. Its core value lies in leveraging its anti-inflammatory effects to circumvent inflammation-mediated tissue damage and maintain the normal physiological functions of the heart-brain axis. This mechanism of action and its application are distinct from those mentioned in any previous contexts.

Hot Tags: glucagon capsules, China glucagon capsules manufacturers, suppliers, HCG Diet Capsules, HCG Powder, Ipamorelin Injection, PT 141 Injection, PT 141 Peptide Spray, Sermorelin Tablet